Human LRIG1 is a single-pass cell-surface protein whose extracellular leucine-rich-repeat and immunoglobulin-like domains participate in receptor regulation. Direct human studies support receptor-specific negative regulation rather than an intrinsic catalytic activity. For EGFR/ERBB receptors, LRIG1 can promote receptor ubiquitination and degradation through c-Cbl recruitment PMID:15282549. A second human study found complexes with all four ERBB receptors in a transfection system PMID:15345710. This is strong positive evidence, but not assay-universal: purified extracellular fragments did not show detectable EGFR binding in another study PMID:25765764.
MET regulation is mechanistically distinct from the c-Cbl model established for EGFR. LRIG1 interacts with MET without HGF stimulation and destabilizes MET independently of cbl PMID:17178829. In the therapeutic-antibody SAIT301 setting, ubiquitinated LRIG1 recruits Hrs and carries the MET-LRIG1 complex toward lysosomal degradation PMID:24828152. USP8 deubiquitinates LRIG1 and thereby modulates this route; this makes LRIG1 a regulated substrate/adaptor in the pathway, not an ubiquitin ligase or deubiquitinase.
RET regulation uses yet another experimentally described mode. Lrig1 associates with RET and suppresses GDNF binding, lipid-raft recruitment, receptor autophosphorylation, MAPK activation, and neuronal differentiation PMID:18171921. With oncogenic RET2A and RET2B, LRIG1 reduces receptor phosphorylation without significantly changing total receptor abundance PMID:29436694. Thus RET inhibition should not automatically be described as receptor degradation.
The membrane-anchored and shed forms must be kept distinct. Full-length LRIG1 is a transmembrane protein PMID:15282549. Cells also constitutively shed LRIG1 ectodomains PMID:21087604, and purified ectodomain inhibited EGF signaling without apparent EGFR downregulation PMID:21087604. ADAM17-sensitive modulation supports metalloprotease-dependent shedding in the tested systems, but the abstract does not establish one obligatory protease or a functionally unique UniProt isoform.
LRIG1 can act as a tumor suppressor in defined settings, but a universal human tumor-suppressor claim is not licensed. In mouse intestine, loss of Lrig1 increased ErbB/ERK signaling and 14 of 16 homozygous mice developed duodenal tumors PMID:22464327. In human thyroid tumor cohorts, LRIG1 expression was reduced, but no significant association with survival was found; moreover, Lrig1 loss did not significantly change the RET2B mouse-model outcome PMID:29436694. EGFRvIII-positive glioblastoma cells provide another specific setting in which ectopic LRIG1 opposes proliferation, survival, motility, and invasion PMID:18542056.
The defensible core is that membrane LRIG1 restrains multiple receptor tyrosine kinase pathways through receptor- and context-dependent mechanisms, including c-Cbl-linked ERBB ubiquitination/degradation, CBL-independent MET destabilization, and inhibition of RET activation. Ectodomain shedding adds a soluble, non-cell-autonomous mode of EGF-pathway inhibition. Generic protein-binding annotations do not express these mechanisms, and screen interactions should remain non-core unless functionally resolved.